Background: PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain) found that initial use of at least 64-slice multidetector computed tomography angiography (CTA) versus functional diagnostic testing strategies did not improve clinical outcomes in stable symptomatic patients with suspected coronary artery disease (CAD) requiring noninvasive testing.
N onacute chest pain is a common reason for patients to seek medical care and a continuing challenge for the medical practitioners who must determine what it represents. Clinicians typically rely on the patient's history and noninvasive tests to assess the possibility of obstructive coronary artery disease (CAD). To date, the evidence base on the effectiveness of the major testing alternatives has largely been limited to observational studies comparing diagnostic accuracy or prognostic significance (1) (2) (3) (4) . Consequently, little consensus exists among clinicians and testing experts on which strategy provides the best outcomes for patients.
PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain) examined the effect of different diagnostic testing strategies for CAD on patient outcomes (5) (Supplement, available at www.annals .org). A detailed description of the overall PROMISE design has been published (5, 6) . Briefly, between 27 July 2010 and 19 September 2013, PROMISE enrolled 10 003 symptomatic outpatients without known CAD at 193 North American sites (5) . Patients were eligible if their physician believed that nonurgent, noninvasive stress testing was indicated for evaluation of their symptoms (6) . Patients were randomly assigned to either initial computed tomography angiography (CTA) (anatomical strategy) or initial prespecified functional testing using stress electrocardiography (ECG), stress echocardiography, or stress nuclear methods, stratified by site (6) . The choice of functional test was left to the patient's clinician, as was the interpretation of the test and all subsequent management after the test. Median follow-up was 25 months (interquartile range, 18 to 34 months). The primary study outcome, a composite of all-cause mortality, myocardial infarction, hospitalization for unstable angina, or major 72-hour complications from diagnostic tests or cardiovascular procedures, occurred in 3.3% of patients in the CTA group and 3.0% of those in the functional testing group (adjusted hazard ratio, 1.04 [95% CI, 0.83 to 1.29] ; P = 0.75) (5) . No individual components of the primary end point, combinations of components, or subgroup anal-
Index Diagnostic Testing Cost Estimation
Cost weights for the index testing procedures were derived from the Premier Research Database (www .premierinc.com) , which contains discharge abstract and cost data for all inpatient and hospital-based outpatient encounters from more than 800 geographically diverse hospitals. Two thirds of these hospitals provide detailed, service-level data from resource-based costaccounting systems, and the remainder provide itemized charges that are converted to costs by using department-level cost-charge ratios (RCCs). To estimate test costs, we extracted data on outpatient encounters for patients aged 45 years or older who were discharged between 1 January and 30 June 2014 with CPT (Current Procedural Terminology) codes for target noninvasive diagnostic tests and cardiac diagnoses.
We used testing cost data from Premier that were generated from bottom-up cost-accounting methods (rather than RCCs) because they provide a detailed resource-based estimate of testing costs in a large group of U.S. hospitals (7) . The facility testing costs used in our base-case analyses were derived from the distribution of these costs (data are shown in Table 1 ).
Hospital Cost Estimation
Medical resource use through the first 60 days was recorded on the study case report form. Further follow-up information was collected from patients by using mail-based (46%) or telephone-based (54%) methods. Resource consumption data covered emergency department visits, days in the hospital, use of intensive care unit services, catheterization and coronary revascularization procedures, and major complications related to procedures. Hospitalizations and hospital-based testing and procedures were verified using medical billing information. Patient reports of hospitalizations that could not be verified were not counted in the analysis.
Hospital-based costs were calculated using hospital billing data (UB-04 forms), with charges converted to costs using the departmental charge-cost conversion factors available from each hospital's annual Medicare cost report. Of the 5863 hospital-based care episodes, we collected billing information for 4876 (83.2%). In all cases, uncollectible billing information from verified hospitalizations was missing due to administrative reasons (such as the hospital declining to provide requested bills) unconnected with the randomized diagnostic strategy, the actual tests received, subsequent care, or patient outcomes. Therefore, we assumed these data were missing at random and used linear re- gression methods to impute cost weights for these records from the portion of the study cohort with complete cost data. The imputation models included reason for hospitalization, type of hospital visit (inpatient vs. emergency department), length of stay, intensive care unit admission during stay, coronary artery bypass grafting surgery (CABG), percutaneous coronary intervention (PCI), and peripheral vascular bypass or stenting. Some catheterization and revascularization procedures were performed on an outpatient basis or were captured as a clinical event but not as a hospitalization; costs for these services were imputed using average prices from services with billing records, as summarized in Appendix Table 1 (available at www.annals .org).
Physician Cost Estimation
Physician costs for the index testing strategy and for any follow-up care shown on the case report form or identified through billing data were estimated by mapping major procedures and physician services to appropriate CPT or Healthcare Common Procedure Coding System codes in the 2014 Medicare national reimbursement schedule. The physician fees assigned to the initial randomized tests in this study are shown in Table 2 .
Statistical Analysis

Descriptive Analyses and General Considerations
All primary comparisons were performed according to the intention-to-treat principle. Descriptive statistics included percentages for discrete variables and medians with interquartile ranges plus means with SDs for continuous variables. The chi-square test was used for discrete variable comparisons, and nonparametric tests, such as the Wilcoxon-Mann-Whitney test, were used for continuous variable comparisons. Follow-up cost data on surviving patients lost to follow-up were assumed to be missing at random and were imputed using linear regression models developed on patients with complete cost data.
Estimation and Comparison of Cumulative Within-Trial Costs
A nonparametric partitioned estimator was used to estimate 3-year medical costs specific to the diagnostic strategy, with 12 partitions corresponding to 3-month intervals after randomization (8). Comparisons between testing strategies were made using a normal approximation, with SEs estimated using the bootstrap approach. To account for uncertainty in test prices, in each bootstrap repetition, we randomly sampled (with replacement) a price weight from the Premier database distribution for each test type and used these price weights to calculate costs during that bootstrap repetition. Bootstrapping was performed using 10 000 repetitions, with percentile-based CIs reported. The primary effect size was the mean cost difference and 95% CI between the groups. P values were calculated for selective comparisons, with a "significant" P value equivalent to a 95% CI that excluded 0. No adjustment in significance levels for multiple comparisons was planned or used. Differences in cost by diagnostic testing group were interpreted in the context of the trial clinical results; we looked for consistency and plausibility with respect to end points as well as measures of resource use.
In addition, we used bootstrap methods to plot the probability of differences in cost greater than arbitrary thresholds of interest (such as $500, $750, or $1000).
Subgroups
Prespecified subgroup analyses were based on age, sex, race, site-generated assessment of pretest probability of CAD, CAD risk equivalent (history of diabetes, peripheral vascular disease, or cerebrovascular disease), Diamond-Forrester/CASS (Coronary Artery Surgery Study) pretest probability of CAD (9), and prerandomization physician choice for functional stress test (5) . To examine the sensitivity of our results to the specific testing cost weights chosen, we performed 2 sensitivity analyses. First, we replaced the bottom-up costaccounting-based test costs with the top-down estimates of test costs from the Premier database, using the sample of hospitals that provided data in terms of charges and cost-charge correction ratios (Appendix Table 2 , available at www.annals.org). Second, we used the 2014 Medicare reimbursements for hospitalbased testing in place of the Premier cost weights (Appendix Table 2 ); this analysis did not substitute Medicare reimbursements for all follow-up tests and was not intended to represent a cost analysis from the Medicare perspective.
Role of the Funding Source
The PROMISE economic study was a prospectively designed part of the PROMISE trial and was funded through a separate R01 grant from the National Heart, Lung, and Blood Institute along with the parent trial. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.
RESULTS
Baseline Characteristics
Baseline characteristics for the economic study cohort were well-balanced by randomized assignment (Appendix Table 3 , available at www.annals.org). The mean age was 60.8 years, 53.1% of patients were female, 87.8% had a primary symptom of chest pain or dyspnea, and the average Diamond-Forrester/CASS pretest probability of CAD was 53.4%. Patients excluded from the economic study were about 1 year younger, less likely to be female, more likely to be a member of a minority group, and more likely to have noncardiac chest pain and had a slightly lower average pretest probability of CAD (Appendix Table 4 , available at www.annals.org).
Medical Costs Analyzed by the Intention-to-Treat Principle
Among patients in the economic study cohort who were randomly assigned to CTA, 4523 (93.9%) had CTA as their initial test, 134 (2.8%) had a functional test, 9 (0.2%) had invasive angiography, and 152 (3.2%) had no diagnostic test. Among those randomly assigned to functional testing, 4523 (93.6%) had a functional test as their initial test, 46 (1.0%) had CTA, 20 (0.4%) had invasive angiography, and 240 (5.0%) had no test.
Costs to 3 Years
Within 90 days after randomization, 12.2% of CTA patients and 8.1% of functional testing patients had follow-up invasive catheterization, and 6.2% of patients in the CTA group versus 3.2% of those in the functional testing group had coronary revascularization. At 90 days, the mean cost for the CTA group was $2494 ver-sus $2240 for the functional testing group, with a mean difference of $254 (95% CI, Ϫ$634 to $906).
Between 91 and 365 days, the mean cost difference between the groups was $99 (CI, Ϫ$136 to $342). Thus, the cumulative 1-year cost difference was $353 (CI, Ϫ$568 to $1071). In year 2, the mean cost difference was $26 (CI, Ϫ$252 to $297), and in year 3, the mean difference was $249 (CI, Ϫ$227 to $811). The 3-year cumulative costs were $7213 for CTA and $6586 for functional testing, with a mean difference of $627 (CI, Ϫ$463 to $1609) ( Figure 1) . None of the 95% CIs excluded the null value (no cost difference). Year 3 results were skewed by an outlier in the CTA group that involved a hospitalization costing more than $300 000 for orthopedic care unrelated to the PROM-ISE testing question. When this observation was removed, the mean difference between the groups in year 3 was reduced to $91 and the cumulative difference was reduced to $469. Other approaches to addressing outliers reduced the mean difference at 3 years to $539, and winsorizing all outlier observations that were less than the first or greater than the 99th percentiles to the first and 99th percentiles, respectively, reduced the mean difference at 3 years to $493.
As shown in Appendix Table 5 (available at www .annals.org), CTA testing costs were $332 lower than functional testing costs. However, by 90 days downstream costs after testing were about $600 higher for patients in the CTA group.
Sensitivity Analyses
The difference in cost between anatomical and functional testing was robust to various alternative price specifications. Using cost weights based on the Medicare Physician Fee Schedule for noninvasive tests, the 90-day cost difference favored CTA slightly (mean difference, Ϫ$32 [CI, Ϫ$314 to $256]), whereas use of the RCC-derived price weights created a larger difference (mean difference, Ϫ$401 [CI, Ϫ$2131 to $619]).
Cost Components
Analysis of costs according to the type of care ( Figure 2 , A) showed that during the initial 90 days, the CTA group saved an average of $378 in additional noninvasive testing costs but had an excess cost of $423 due to invasive catheterization and revascularization as well as $166 in other cardiovascular inpatient care. After 90 days, costs were low in all categories and equivalent between the 2 strategies. Most of the excess $249 cost for CTA in year 3 (Figure 2 , D) was due to an average of $256 in extra noncardiovascular inpatient care.
In our base-case analysis, the cost distribution for the CTA patients shifted upward relative to the functional testing patients ( Figure 3) . Because of the outlier effects in year 3, we believed that year 2 data best represented the relevant probabilities. Specifically, our analysis indicated that costs in the CTA group would exceed those in the functional testing group by no more than $500 in 58.6% of 1000 bootstrap samples, by no more than $750 in 79.7% of samples, and by no more than $1000 in 93.4% of samples. When we sub- 
ORIGINAL RESEARCH
Economic Outcomes With Anatomical vs. Functional Diagnostic Testing for CAD stituted the Premier RCC cost weights in our sensitivity analysis, costs in the CTA group exceeded those in the functional testing group by no more than $500 in 89.9% of bootstrap samples, and 63.4% of samples had a cost difference of no more than $0 (that is, lower costs in the CTA group than the functional testing group) (Appendix Figure 1 , top, available at www.annals.org).
With Medicare cost weights for hospital-based testing, 94.7% of samples had a cost difference of no more than $500 and 38% of samples had a cost difference of no more than $0 (Appendix Figure 1, bottom) .
Prespecified Subgroup Analysis
Five prespecified subgroups did not differ importantly from the overall result ( Figure 4 ). For patients who had a high site-generated pretest probability of CAD (n = 431) or a high Diamond-Forrester pretest probability of CAD (n = 482), the CTA group had a mean cost difference in excess of $2000 at 90 days ( Figure 4 ). The primary cost drivers for these differences were extra revascularization procedures, but costs were also higher for the categories of other cardiovascular care and noncardiovascular care (Appendix Table 6 , available at www.annals.org). Mean cost differences (CTA minus functional testing) were similar in prespecified subgroups when Medicare pricing (Appendix Figure 2 , top, available at www.annals.org) and RCC pricing (Appendix Figure 2 , bottom) were used.
DISCUSSION
In this economic analysis of PROMISE, we have shown that an initial CTA strategy had costs similar to those of a functional stress testing strategy, although the patterns of care differed. Specifically, the CTA group had less follow-up noninvasive testing and more invasive catheterization and revascularization. Our data suggest that, after 90 days, little happened to these patients out to 3 years that was driven specifically by which testing strategy they received.
Interpretation of empirical cost comparisons in which the clinical and cost outcomes are similar poses important challenges. One possible interpretation of our results is that the CTA strategy was modestly more costly than the functional testing strategy and our study had insufficient precision to exclude the null case (no cost difference). No criteria have been established for defining how small a numerical difference must be for costs to qualify as "similar" (a notion akin to "noninferior" in the comparison of clinical outcomes). Instead of using fixed decision rules to interpret cost data, as is typical for clinical outcome comparisons, health economics has developed methods that recognize that policymakers vary both in their willingness to tolerate uncertainty about the "true" cost difference and in the threshold cost difference they consider important. Four lines of evidence support the case that the costs for CTA and functional testing strategies are similar. First, the mean cost at 90 days was $254 higher for CTA, with an additional $99 in extra costs between 91 days and 1 year. Because the cumulative 1-year difference ($353) represents a shift equivalent to about 4% of the SD of the 0-to-12-month partitioned cost estimator ($9436), it provides a useful, if imperfect, reference point for assessing the magnitude of the differences we observed. Second, the mean cost difference was $26 in year 2 and $249 in year 3 (which decreased to $91 after removal of 1 very-high-cost noncardiovascular outlier). These data provide strong evidence that the randomized diagnostic testing strategy had no discernable net effect on costs after the first year. Third, our bootstrap analysis of the 2-year cost difference ( Figure 3) showed that 59% of bootstrap repetitions had a cost difference of $500 (4% of the SD of the 2-year partitioned estimator [$12 242]) or less, and 80% of repetitions had a difference of $750 (6% of the SD of the 2-year cost) or less. Finally, in sensitivity analyses where we used either Medicare Physician Fee Schedule cost weights or the top-down RCC method, costs in the CTA group were numerically lower than in the functional testing group.
To date, there have been few large multicenter empirical studies of the long-term costs and resource consumption effects of coronary CTA relative to alternative diagnostic imaging strategies. In a consecutive cohort study (2005 to 2007) from an academic institution in Ottawa, Canada, Chow and colleagues found that implementation of a cardiac computed tomography program (February 2006) was associated with a decrease in the frequency of normal invasive coronary angiography from 31.5% to 26.8% (10). A retrospective cohort study (2005 to 2008) from the U.S. Medicare population (aged ≥66 years) compared the effects of coronary CTA with functional stress testing options on subsequent catheterization, revascularization, and costs out to 180 days (11). Computed tomography angiography was associated with about a 2-fold increase in referral to invasive catheterization, a 2.5-fold increase in PCIs, and a 3-fold increase in CABG after adjustment. Coronary artery disease-related costs after CTA were almost 40% higher than with stress perfusion imaging at 180 days ($14 943 vs. $10 626). Finally, in a 41-center prospective cohort study (2006 to 2008) involving 1703 patients with suspected CAD, 2-year unadjusted costs for CAD management were about $1000 higher for CTA than for stress perfusion imaging (12). After adjustment for baseline differences, CTA costs remained 15% higher. The extra costs of CTA were driven by more frequent use of invasive catheterization (13% vs. 4% for stress nuclear testing at 90 days), as well as more PCIs (6% vs. 1% at 90 days) and CABG (2% vs. 0.4%). Thus, observational studies reflecting data from 2005 to 2008 suggested that CTA would modestly reduce referral to catheterization for patients with normal coronary arteries but would increase use of invasive catheterization and revascularization overall, with an associated net increase in medical costs. These patterns were also seen in PROMISE, which enrolled patients from 2010 to 2013, but the magnitude of the effect on incremental medical costs compared with functional testing was much lower than these earlier studies predicted.
PLATFORM (Prospective Longitudinal Trial of FFR CT Outcomes and Resource Impacts) recently reported an economic comparison of 204 European patients with stable chest pain who had intermediate likelihood for CAD and were managed either with stress testing or usual care or with fractional flow reserve (FFR) CTA imaging (13). Using Medicare reimbursement rates to estimate costs, Hlatky and colleagues found that 90-day costs did not significantly differ between strategies (mean difference, $542 [CI, Ϫ$1153 to $2237]). No difference was seen in the use of invasive catheterization, but the FFR CT strategy resulted in about 6 more PCIs and 1 fewer CABG per 100 patients. Although these results are from a much smaller sample from a different geographic region (Europe vs. the United States), with a different CTA strategy (FFR in 60%) and a different usual care strategy (60% had CTA without FFR), they are reasonably concordant with our findings.
Of the 7 prespecified subgroup comparisons in PROMISE, 5 had cost results consistent with those in the overall comparison. Both measures of high pretest probability of CAD were associated with significantly higher cost at 90 days for CTA ( Figure 4) due to greater use of invasive catheterization and revascularization among patients in that group. These high-probability subgroups are too small to allow reliable assessment of outcome differences produced by these different treatment patterns. However, this finding does show that the modest trend toward higher costs for CTA in our base-case cost comparison was due mostly to differ- 
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Our study has limitations. The initial diagnostic test costs used in our analysis were derived from data from outside the trial, which was necessitated by the lack of suitable cost weights from the trial patients. There are no standard methods for converting the charges for an office-based test in the United States to the relevant resource-based cost. Thus, we used data from the Premier Research Database to provide these cost weights because the database reflects the input of many hospital-based testing laboratories and is provided in a cost-accounting format that shows not only the total facility cost of testing but also the key component costs. Also, we did not include the costs of outpatient medications, routine outpatient medical care, or patient and caregiver time because of budget constraints. Given the similarity in the costs of the 2 diagnostic strategies compared in PROMISE, regional variation in the relative costs of functional versus anatomical testing and in the type of functional testing preferred may result in net cost positions that differ from those reported for the trial overall.
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